Ann: Half-year Shareholder Update, page-10

Acadia has announced the acquisition of a private US biotech, CerSci Therapeutics.

Acadia paid US$52.5 million upfront in a cash-and-stock deal— US$47.2 million of it in Acadia shares. CerSci shareholders will also be eligible for up to US$887 million more in payments, plus royalties, dependent on development, commercialization, and sales milestones being met.

CerSci’s lead, early-stage asset is ACP-044, a potential therapy for both acute post-surgical and chronic nerve pain, which is designed to interfere with multiple pain pathways without presenting an addiction risk. A Phase 1 trial is planned for H1 2021.

CerSci also has preclinical programs in migraine and painful diabetic neuropathy and discovery-stage programs in neurodegenerative disease and opioid use disorder.

https://ir.acadia-pharm.com/sec-filings
https://www.fiercebiotech.com/biotech/acadia-adds-pain-meds-to-pipeline-52-5m-cersci-buyout
https://xconomy.com/san-diego/2020/...s-cersci-potential-pain-meds-in-52-5m-buyout/
https://cersci.com/